Dr. Karin A. Provost, D.O., PHD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Midwestern University, Chicago College of Osteopathic Med (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 49
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Midwestern University, Chicago College of Osteopathic Med
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NY license 249836-1 -
Critical Care Medicine (Internal Medicine) Physician
NY license 249836-1 -
Internal Medicine Physician
NY license 249836-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Kaleida Health Buffalo, NY
Medical groups
- Academic Medicine Services, Inc. (115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 49
- Services billed
- 143
- Patients’ average age
- 65
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 44 | 29 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Williamsville, NY | 76 |
| Montelukast Sodium Other prescribers in Williamsville, NY | 68 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in Williamsville, NY | 63 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Williamsville, NY | 50 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Williamsville, NY | 39 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Williamsville, NY | 38 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Williamsville, NY | 34 |
| Azelastine Hcl Other prescribers in Williamsville, NY | 34 |
| Fluticasone Propionate Other prescribers in Williamsville, NY | 33 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Williamsville, NY | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $16.24 in total to this clinician.
| Insmed, Inc. | $16.24 |
|---|
| Education | $16.24 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Jun 9, 2025 | Education Arikayce · Respiratory · in-kind | $16.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $198,386 in research payments for these studies, mostly to the institutions running them.
- Defining the lmpact of Budesonide, Fluticasone Propionate and Fluticasone Furoate on the Alveolar Macrophage lmmune Response to Community Acquired Pneumonia Pathogens in
AstraZeneca Pharmaceuticals LP - A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04751487
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.